Inhibition of PD-L1 using drug MPDL3280A for patients with metastatic urothelial bladder cancer

ASCO 2014 roundup

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

Cancer evasion of the immune system: the fundamentals

Lecture: PSA Screening - Where East meets West

Lecture: Current use of systemic therapies in localised disease

Lecture: Current standard of care in advanced disease

Lecture: Exploring the androgen signalling pathway in CRPC

Lecture: Clinical perspectives: Non-AR therapeutic targets in CRPC

Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (for)